STOCK TITAN

HUTCHMED's three drugs to keep China coverage in 2027

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
6-K

Rhea-AI Filing Summary

HUTCHMED (China) Limited said China’s updated National Reimbursement Drug List, effective January 1, 2027, will continue to include ELUNATE, ORPATHYS and SULANDA. Following a contract renewal with China’s National Healthcare Security Administration, the update expands coverage for new indications, renews agreements for existing indications and maintains coverage under current multi-year agreements.

The list is updated annually, and inclusion is subject to renewal every two years. As of the end of 2025, 1.33 billion people in China had basic medical insurance, around 95% of the population. Reimbursement for Category B medicines requires patient copayments that vary by province and insurance scheme.

Updated NRDL effective date January 1, 2027 Effective date of the updated list
People with basic medical insurance 1.33 billion people China, as of the end of 2025
Share of population with basic medical insurance Around 95% China, as of the end of 2025
National Reimbursement Drug List regulatory
"updated National Reimbursement Drug List (NRDL)"
A national reimbursement drug list is an official list of medicines that a country's public health system agrees to pay for, fully or in part, so patients pay little or nothing. Think of it like a government-approved shopping list that makes certain drugs affordable and widely available; inclusion usually boosts a drug’s sales and predictable pricing, while exclusion can limit market access and revenue, making it a key factor for investors assessing a drug maker’s future earnings.
Category B medicines regulatory
"Reimbursement of Category B medicines"
copayment financial
"varying degrees of copayment from patients"
VEGFR -1, -2 and -3 medical
"selective oral inhibitor of all three VEGFR -1, -2 and -3"
MET tyrosine kinase inhibitor medical
"potent and highly selective MET tyrosine kinase inhibitor"
angio-immuno kinase inhibitor medical
"novel, oral angio-immuno kinase inhibitor"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which HUTCHMED (HCM) medicines remain on China’s updated NRDL?

The updated NRDL will continue to include ELUNATE, ORPATHYS and SULANDA. The update follows a contract renewal with China’s National Healthcare Security Administration and reflects expanded coverage for new indications, renewed agreements for existing indications, and continued inclusion under current multi-year agreements.

When does HCM’s updated NRDL coverage take effect?

The updated NRDL takes effect on January 1, 2027. The NRDL is updated annually, and inclusion is subject to renewal every two years.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

​

​

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

​


​

FORM 6-K

​


​

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE

SECURITIES EXCHANGE ACT OF 1934

​

For the Month of November 2026

​

Commission File Number: 001-37710

​


​

HUTCHMED (CHINA) LIMITED

(Translation of registrant’s name into English)

​


​

48th Floor, Cheung Kong Center, 2 Queen’s Road Central, Hong Kong

(Address of principal executive offices)

​


​

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

​

Form 20-F  ⌧             Form 40-F  ◻

​

​

​

​


​

HUTCHMED (CHINA) LIMITED

​

Form 6-K

​

EXHIBIT INDEX

​

Exhibit No.

  ​ ​ ​

Description

​

​

​

Exhibit 99.1

​

Press release relating to HUTCHMED announces expanded coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®

​

​

​

​

​

​

​

2


​

​

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

​

​

​

HUTCHMED (CHINA) LIMITED

​

​

​

​

​

​

​

By:

/s/ Johnny Cheng

​

Name:

Johnny Cheng

​

Title:

Chief Financial Officer

​

​

Date: November 16, 2026

3


Exhibit 99.1

​

Graphic

​

Press Release

​

HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS®

​

Hong Kong, Shanghai & Florham Park, NJ — Monday, November 16, 2026: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that following the contract renewal with the China National Healthcare Security Administration (“NHSA”), the updated National Reimbursement Drug List (“NRDL”) effective on January 1, 2027 will continue to include ELUNATE®, ORPATHYS® and SULANDA®. This update reflects expanded coverage for new indications, renewed agreements for existing indications, as well as continued inclusion under current multi-year agreements.

​

Newly Included and Renewed Indications in the Updated NRDL:

​

●ELUNATE® (fruquintinib) is newly included for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior vascular endothelial growth factor receptor (“VEGFR”) tyrosine kinase inhibitors (“TKI”) therapy and have not received programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor therapy in the first-line setting, in combination with sintilimab injection.

​

●ORPATHYS® (savolitinib) is newly included for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (“EGFR”) mutation-positive non-squamous non-small cell lung cancer (“NSCLC”) with MET amplification after disease progression on EGFR-TKI therapy, in combination with osimertinib. It is also renewed for the treatment of adult patients with locally advanced or metastatic NSCLC with MET exon 14 skipping alteration. 

​

In addition to the above updates, the NRDL maintains coverage for all other previously included indications for ELUNATE®, ORPATHYS® and SULANDA® under their current multi-year agreement.

​

The government in China has placed great importance on improving the affordability of drug treatments for the public. As of end of 2025, 1.33 billion people in China had basic medical insurance coverage, representing around 95% of the entire population. The NRDL is updated every year, and inclusion on the list is subject to renewal every two years. The NHSA annually convenes a broad network of experts in medicine, pharmacology, pharmacoeconomics and actuarial valuation to identify innovative medicines to consider for NRDL inclusion. Reimbursement of Category B medicines, including novel oncology medicines, requires varying degrees of copayment from patients, depending on their provinces or types of NHSA insurance scheme enrollment.

​

About Fruquintinib

Fruquintinib is a selective oral inhibitor of all three VEGFR -1, -2 and -3. Fruquintinib is co-developed and co-commercialized in China by HUTCHMED and Eli Lilly and Company under the brand name ELUNATE®. Takeda holds the exclusive worldwide license to further develop, commercialize, and manufacture fruquintinib outside mainland China, Hong Kong and Macau, marketing it under the brand name FRUZAQLA®.

​

About Savolitinib

Savolitinib is an oral, potent and highly selective MET tyrosine kinase inhibitor that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations), gene amplification or protein overexpression. Savolitinib is being jointly developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca under the brand name ORPATHYS®.

​


About Surufatinib

Surufatinib is a novel, oral angio-immuno kinase inhibitor that selectively inhibits the tyrosine kinase activity associated with VEGFRs and fibroblast growth factor receptor (FGFR), which both inhibit angiogenesis, and colony stimulating factor-1 receptor (CSF-1R), which regulates tumor-associated macrophages, promoting the body’s immune response against tumor cells. Surufatinib is marketed in China by HUTCHMED under the brand name SULANDA®. HUTCHMED currently retains all rights to surufatinib worldwide.

​

​

About HUTCHMED

HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. Since inception it has focused on bringing drug candidates from in-house discovery to patients around the world, with its first four medicines marketed in China, the first of which is also approved around the world including in the US, Europe and Japan. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.

​

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events, including its expectations for the commercialization of fruquintinib, savolitinib and surufatinib in China, the potential benefits and further clinical development of fruquintinib, savolitinib and surufatinib, its expectations as to whether further studies would meet their primary or secondary endpoints, and its expectations as to the timing of the completion and the release of results from such studies. Forward-looking statements involve risks and uncertainties. Such risks and uncertainties include, among other things, assumptions regarding the commercial acceptance of fruquintinib, savolitinib and surufatinib, the impact of the inclusion of fruquintinib, savolitinib and surufatinib on the NRDL on sales of the drug and its pricing, clinical trial enrollment rates, timing and availability of subjects meeting a study’s inclusion and exclusion criteria, changes to clinical protocols or regulatory requirements, unexpected adverse events or safety issues, the ability of fruquintinib, savolitinib and surufatinib to obtain regulatory approval for a targeted indication in different jurisdictions and the sufficiency of funding. In addition, as certain studies rely on the use of other drug products such as sintilimab or osimertinib as combination therapeutics, such risks and uncertainties include assumptions regarding their safety, efficacy, supply and continued regulatory approval. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the US Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise.

​

Medical Information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

​

​

CONTACTS

Investor Enquiries

+852 2121 8200 / ir@hutch-med.com

 

Media Enquiries

FTI Consulting –

+44 20 3727 1030 / HUTCHMED@fticonsulting.com

  ​ ​Ben Atwell / Tim Stamper

  ​ ​+44 7771 913 902 (Mobile) / +44 7779 436 698 (Mobile)

Brunswick – Zhou Yi

+852 9783 6894 (Mobile) / HUTCHMED@brunswickgroup.com

 

Panmure Liberum

Nominated Advisor and Joint Broker

Atholl Tweedie / Emma Earl / Rupert Dearden

+44 20 7886 2500

 

Cavendish

Joint Broker

Geoff Nash / Nigel Birks

+44 20 7220 0500

 

Deutsche Numis

Joint Broker

Duncan Monteith / Ramin Naji

+44 20 7545 8000

​


Filing Exhibits & Attachments

1 document

Keep reading